Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstruction

niversity Hospital Ghent0 个研究点目标入组 40 人开始时间: 2009年7月1日最近更新: 2021年6月7日

适应症

试验速览

暂无简介。

•Patient MUST satisfy ALL of the following inclusion criteria before he/she will be allowed to participate in the study:
•Patient have to give written (personally signed and dated) informed consent before completing any study-related procedure.
•Demographic criteria
•=18 years of age.
•Criteria related to the disease
•diagnosis of a digestive obstruction of malignant origin, confirmed by a CT scan within the previous 3 months,
•inoperability as decided after surgical consultation
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•If any of the following applies, the patient MAY NOT enter in the study:
•Criteria related to the disease:
•operable obstruction,
•bowel obstruction that can be explained by a non malignant cause (e.g. hypokaliaemia, drug side-effects, renal insufficiency),
•signs of bowel perforation,
•Criteria related to the studied treatment:
•prior treatment with somatostatin or any analogue as treatment of the bowel obstruction in the last 60 days,
•a known hypersensitivity to any of the test materials or related compounds.
•Other criteria
•previously enrolment in this study.
•female patients who are lactating or child bearing potential without adequate contraceptive measures.

发起方

niversity Hospital Ghent